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Introduction
The current treatment recommended by guidelines
for persistent asthma is a ﬁxed-dose inhaled cortico-
steroid (ICS) or an ICS/long-acting b2-agonist
(LABA) combination administered twice daily (bid),
plus a short-acting b2-agonist (SABA) as needed for
symptom relief. The two ICS/LABA combination
inhalers currently available – budesonide/formoterol
and salmeterol/ﬂuticasone – are highly effective at
providing early and sustained improvements in
asthma control for patients symptomatic on ICS
alone (1–3).
Even with such treatments, asthma control remains
suboptimal (4). Residual asthma symptoms can
persist, even in patients using regular ICS or ICS/
LABA maintenance therapy, with exacerbations ran-
ging from mild increases in symptoms to events
requiring medical intervention or hospitalisation
(1,5,6). Consequently, asthma management plans
have been developed that specify treatment changes
in response to increasing symptoms or deteriorating
lung function. These effectively reduce the rate of
exacerbations (7), but require detailed physician
guidance and patient adherence. Despite strong advo-
cacy and evidence of effectiveness, the use of asthma
management plans remains disappointingly low (8).
A new approach to asthma therapy is budesonide/
formoterol (Symbicort
 ) maintenance and reliever
therapy (SMART) using one inhaler, without the
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SUMMARY
This randomised, double-blind, 6-month study compared budesonide/formoterol for
maintenance and relief with salmeterol/ﬂuticasone and a ﬁxed maintenance dose
of budesonide/formoterol, both with terbutaline for relief. Following a 2-week
run-in, 3335 symptomatic adults and adolescents (mean FEV1 73% predicted,
mean inhaled corticosteroid dose 745 lg/day) received budesonide/formoterol 160/
4.5 lg one inhalation bid plus additional inhalations as needed, salmeterol/ﬂutica-
sone 25/125 lg two inhalations bid plus as-needed terbutaline or budesonide/for-
moterol 320/9 lg one inhalation bid plus as-needed terbutaline. Budesonide/
formoterol for maintenance and relief prolonged the time to ﬁrst severe exacerba-
tion requiring hospitalisation, emergency room treatment or oral steroids (primary
variable) vs. ﬁxed-dose salmeterol/ﬂuticasone and budesonide/formoterol (p ¼
0.0034 and p ¼ 0.023 respectively; log-rank test). Exacerbation rates were 19, 16
and 12 events/100 patients/6 months for salmeterol/ﬂuticasone, ﬁxed-dose budeso-
nide/formoterol and budesonide/formoterol for maintenance and relief, respectively,
[rate reduction vs. ﬁxed-dose salmeterol/ﬂuticasone (0.61; 95% CI 0.49–0.76,
p < 0.001) and vs. ﬁxed-dose budesonide/formoterol (0.72; 95% CI 0.57–0.90,
p ¼ 0.0048)]. Budesonide/formoterol maintenance and relief patients used less
inhaled corticosteroid vs. salmeterol/ﬂuticasone and ﬁxed-dose budesonide/formo-
terol patients. All treatments provided similar marked improvements in lung func-
tion, asthma control days and asthma-related quality of life. Budesonide/formoterol
for maintenance and relief reduces asthma exacerbations and maintains similar
daily asthma control at a lower overall drug load compared with ﬁxed-dose salme-
terol/ﬂuticasone and budesonide/formoterol.
What’s known
Clinical evidence has shown that asthma
management using budesonide/formoterol
(Symbicort
 ) maintenance and reliever therapy
(SMART) provides a simpler and more effective
treatment strategy than traditional approaches with
short-acting b2-agonist (SABA) therapy. SMART
improves daily symptom control and prevents
severe exacerbations more effectively than higher
doses of inhaled corticosteroid (ICS) plus SABA or
the same maintenance dose of budesonide/
formoterol plus as-needed terbutaline or formoterol.
The SMART approach has been recommended in
the recent GINA guidelines.
What’s new
The evidence within this manuscript conﬁrms that
patients randomised to receive SMART therapy have
greater protection from severe asthma
exacerbations, including hospitalisations and
emergency room treatment, than those treated
even with higher traditional ﬁxed-dose ICS/long-
acting b2-agonist (LABA) treatment. Similar levels
of daily asthma symptom control were observed
compared with treatment with salmeterol/
ﬂuticasone or ﬁxed-dose budesonide/formoterol.
The observed improvements in overall asthma
control occurred despite a 50% reduction in regular
maintenance doses of ICS/LABA with the SMART
approach.
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treatment approach has also been endorsed in the
latest Global Initiative for Asthma (GINA) guidelines
(13). The simple substitution of budesonide/formo-
terol for SABA allows the dose of controller medica-
tion, LABA and ICS, to be increased quickly in
response to symptoms, while simultaneously offering
rapid symptom relief. A previous study has shown
that SMART is more effective at reducing exacerba-
tions and improving daily asthma control than the
same maintenance dose of budesonide/formoterol
plus as-needed SABA (9). In that study, however,
SMART patients used, on average, a higher daily
dose of budesonide/formoterol than ﬁxed-dose
budesonide/formoterol patients. Therefore, a com-
parison of the efﬁcacy of SMART with that of a
higher maintenance dose of ICS/LABA was needed to
answer two remaining questions: could SMART be as
effective at reducing exacerbations as a higher ﬁxed
maintenance dose of combination therapy and would
SMART result in greater day-to-day ﬂuctuations in
asthma control?
Using a double-blind approach, we hypothesised
that SMART (budesonide/formoterol 160/4.5 lg one
inhalation bid plus additional as-needed inhalations
for relief) would prevent exacerbations more effect-
ively than a ﬁxed dose of salmeterol/ﬂuticasone (25/
125 lg two inhalations bid) plus terbutaline or a
comparable ﬁxed maintenance dose of budesonide/
formoterol (320/9 lg one inhalation bid) plus ter-
butaline as needed (1,14), and that this important
beneﬁt would not be achieved at the expense of daily
asthma control.
Methods
In this study (study code SD-039-0735), outpa-
tients aged ‡ 12 years with a diagnosis of asthma
[as deﬁned by the American Thoracic Society (15)]
for ‡ 6 months and using ICS for ‡ 3 months
[‡ 500 lg/day of budesonide or ﬂuticasone (or
‡ 1000 lg/day of another ICS) for ‡ 1 month]
were eligible for enrolment. Patients had to have a
forced expiratory volume in 1 s (FEV1) ‡ 50% pre-
dicted normal with ‡ 12% reversibility following
terbutaline 1 mg and ‡ 1 asthma exacerbation in
the previous 1–12 months. Patients using reliever
medication on ‡ 5 of the last 7 days of the 2-week
run-in were randomised; those with > 10 as-needed
inhalations in any day of run-in and patients who
experienced an asthma exacerbation during run-in
were not randomised. Patients using systemic corti-
costeroids or with respiratory infections affecting
asthma control within 30 days of study entry were
excluded.
Study design
This 6-month, randomised, double-blind, double-
dummy, parallel-group study was conducted accord-
ing to the Declaration of Helsinki and Good Clinical
Practice guidelines. Independent ethics committees
approved the study protocol, patient information and
consent forms. All patients and parents/guardians of
adolescents gave written informed consent. The ﬁrst
patient was enrolled on 19 December 2003 and the last
patient completed the study on 11 March 2005.
Patients attended the clinic at the beginning and
end of run-in (visits 1–2), and after 8, 16 and
24 weeks of treatment (visits 3–5 respectively). Dur-
ing run-in, patients used their regular ICS for main-
tenance and terbutaline (Bricanyl
  Turbuhaler
 ;
AstraZeneca, Lund, Sweden) for symptom relief. ICS/
LABA combination inhalers were stopped 72 h before
study entry and the corresponding ICS dose used.
Following run-in, eligible patients were randomised
to one of three treatment groups for 24 weeks
(Figure 1): budesonide/formoterol (Symbicort
  Tur-
buhaler
 ; AstraZeneca, Sweden) 160/4.5 lg one inha-
lation bid for maintenance plus additional inhalations
as needed (Symbicort SMART
 ), ﬁxed-dose salmeter-
ol/ﬂuticasone [Seretide
TM/Advair
TM Evohaler
TM
(pressurised metered-dose inhaler, pMDI), Glaxo-
SmithKline, Uxbridge, UK] 25/125 lg two inhalations
bid plus terbutaline as reliever medication or budeso-
nide/formoterol 320/9 lg one inhalation bid plus ter-
butaline. The salmeterol/ﬂuticasone dose, delivered
via a dry-powder inhaler (DPI), has been shown in
previous studies to have similar clinical efﬁcacy to the
ﬁxed dose of budesonide/formoterol used in this
study (1,14). In addition, therapeutic equivalence has
been reported for salmeterol/ﬂuticasone delivered via
either DPI or pMDI (16,17).
At the start of the study, all patients were instruc-
ted in the correct use of the Turbuhaler and the Evo-
haler devices. As an additional safety precaution, any
patient who required > 10 inhalations of reliever
medication on any 1 day was asked to contact the
investigator for reassessment.
Randomisation and blinding
The randomisation schedule was computer-gener-
ated at AstraZeneca Research and Development,
Charnwood, UK. Within each centre, patients were
randomised strictly sequentially as they became eli-
gible. Individual treatment codes and code enve-
lopes (indicating the treatment allocation for each
randomised patient) were provided, but code enve-
lopes were to be opened only in case of medical
emergencies.
To maintain the blinding, all patients received
three inhalers. Patients were instructed to take one
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onide/formoterol or placebo Turbuhaler) and two
inhalations from the pMDI (salmeterol/ﬂuticasone
or placebo Evohaler) upon rising and before going
to bed; for symptom relief, as-needed inhalations
were to be taken from the inhaler with the white grip
(budesonide/formoterol or terbutaline Turbuhaler).
Efﬁcacy measures
The primary objective of this study was to com-
pare the efﬁcacy of SMART [budesonide/formoterol
(160/4.5 lg one inhalation bid) plus additional
inhalations as needed], with salmeterol/ﬂuticasone
(25/125 lg two inhalations bid) plus terbutaline
(0.4 mg/inhalation as needed). The primary variable
was the time to ﬁrst severe exacerbation. Severe exac-
erbations were deﬁned as deterioration in asthma
resulting in hospitalisation or emergency room (ER)
treatment, or the need for oral steroids for ‡ 3 days
(as judged by the investigator). To ensure that the
results obtained were not speciﬁc to choice of ICS/
LABA combination therapy or delivery device, prede-
ﬁned secondary objectives investigated were a combi-
nation of the efﬁcacy of SMART vs. budesonide/
formoterol (320/9 lg one inhalation bid) plus ter-
butaline (0.4 mg/inhalation as needed) both deliv-
ered by Turbuhaler, with an additional comparison
of the efﬁcacy between the two ﬁxed-dose ICS/LABA
regimen. Secondary outcome variables were the
total numbers of severe exacerbations; inhalations of
as-needed medication; change in morning and even-
ing peak expiratory ﬂow (PEF), FEV1, asthma symp-
tom score, nights with awakenings caused by asthma,
symptom-free days, as-needed-free days, asthma-con-
trol days and the number of mild exacerbations.
Patients completed a daily diary throughout the
study in which they recorded PEF, symptoms, reliever
use and intake of maintenance medication. Adherence
to prescribed treatment was checked by the investi-
gator at every visit. Daytime and night-time asthma
symptom scores, measured on a scale of 0–3 (where
0 ¼ no symptoms and 3 ¼ incapacitating symptoms),
were also recorded; these scores were summed to
obtain the total daily score (range 0–6). The percent-
age of symptom-free days, nights free of awakenings,
reliever-free days and asthma control days (a night
and a day without asthma symptoms, no night-time
awakenings caused by asthma and no reliever use)
were calculated from diary-card data. Mild exacer-
bation days, deﬁned as a day with any one of the
following: morning PEF ‡ 20% below baseline, daily
as-needed medication use ‡ 2 inhalations above base-
line or a night with an asthma-related awakening, were
also calculated from diary-card data. A mild exacerba-
tion was deﬁned as two consecutive mild exacerbation
days satisfying the same criterion.
Figure 1 Patient ﬂow. bid, twice daily; ICS, inhaled corticosteroid; SMART, Symbicort
  maintenance and reliever therapy.
Terbutaline dose expressed as 0.5 mg/inhalation metered dose corresponds to 0.4 mg/inhalation delivered dose
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recommended by the European Respiratory Society
(18), at each clinic visit. The best of three satisfactory
FEV1 tests was recorded (18,19). Following instruc-
tion, patients recorded morning and evening PEF
using a Mini-Wright
  peak ﬂow meter (Clement
Clarke, Harlow, UK). Measurements were to be car-
ried out before inhalation of the study medication.
The highest of three consecutive measurements was
recorded.
The Asthma Control Questionnaire (ACQ) 5-item
version (ACQ-5) (20,21) and Asthma Quality of Life
Questionnaire [standardised version; AQLQ(S)] (22)
were self-administered at clinic visits.
Tolerability was assessed by the recording of
adverse events at clinic visits. Investigators were pro-
vided with a set of instructions to be used for the
interpretation of causality judgement.
Overall ICS treatment load was compared between
groups by converting ICS doses to beclomethasone
dipropionate (BDP)-equivalent ICS doses. These cal-
culations were based on the GINA (13) estimates of
equipotence of ICS doses as metered doses: ﬂutica-
sone 500 lg ¼ budesonide 800 lg ¼ beclomethasone
1000 lg; 800 lg budesonide metered dose ¼ 640 lg
delivered dose.
Statistical analysis
The study was powered to detect a difference in the
primary end-point (time to ﬁrst severe exacerbation).
With a total of 1000 patients/group, a log-rank test (at
the two-sided 5% signiﬁcance level) had a 90% chance
of detecting a difference between treatment groups,
assuming a true difference of 20% vs. 14.5% in the
proportion of patients experiencing a severe exacerba-
tion (23). All patients with data after randomisation
were included in the intention-to-treat population for
all efﬁcacy analyses. The safety analyses were based on
all patients who received ‡ 1 dose of study drug.
The time to ﬁrst severe exacerbation was described
using Kaplan–Meier plots and was compared
between treatments using a log-rank test. Further
description of treatment differences was obtained
using a Cox proportional hazards model stratiﬁed by
country, with treatment as a factor. The total num-
ber of severe exacerbations was compared between
treatment groups using a Poisson regression model,
with treatment and country as factors and time in
the study as an offset variable.
Changes in diary-card variables from the average
value during run-in (average value over the last
10 days of run-in) to the average value during the
treatment period were compared between treatments
using an analysis of variance (ANOVA) model, with
treatment and country as ﬁxed factors and the run-in
means as a covariate. Change in FEV1 from baseline
to the average value during visits 3–5 was analysed
using a similar ANOVA, with baseline values as a
covariate. The ACQ and AQLQ(S) overall scores
were analysed in the same way as FEV1, with the
exception that, for AQLQ(S), the change from base-
line to the last visit on treatment was used.
Results
Patient proﬁle
Patient ﬂow is summarised in Figure 1. Of the 4399
patients enrolled at 235 centres in 16 countries, 3335
were randomised to treatment. The most common
reasons for exclusion from randomisation were fail-
ure to meet deﬁned criteria for asthma severity, spe-
ciﬁcally spirometry criteria and use of as-needed
medication during the run-in period. There were 409
protocol deviations in 327 patients, none of which
justiﬁed exclusion of data from the analysis. Patient
demographics are shown in Table 1. Self-reported
adherence to maintenance medication was high; 99%
of patients in all groups reported taking more than
81% of their maintenance medication.
Severe exacerbations
SMART prolonged the time to ﬁrst severe exacerba-
tion compared with ﬁxed-dose salmeterol/ﬂuticasone
and budesonide/formoterol (log-rank test p ¼ 0.0034
and p ¼ 0.023 respectively; Figure 2). There was a
33% reduction in the hazard ratio (HR) for a ﬁrst
severe exacerbation with SMART compared with
salmeterol/ﬂuticasone [HR 0.67; 95% conﬁdence
interval (CI) 0.52–0.87; p ¼ 0.003] and a 26% reduc-
tion compared with ﬁxed-dose budesonide/formoter-
ol (HR 0.74; 95% CI 0.56–0.96; p ¼ 0.026). The two
ﬁxed-dose groups did not differ with respect to time
to ﬁrst severe exacerbation (Table 2). The total num-
ber of severe asthma exacerbations was reduced by
39% [relative rate (RR) 0.61; 95% CI 0.49–0.76;
p < 0.001] in the SMART group compared with
ﬁxed-dose salmeterol/ﬂuticasone and by 28% (RR
0.72; 95% CI 0.57–0.90; p ¼ 0.0048) compared with
ﬁxed-dose budesonide/formoterol. The total number
of exacerbations was similar in the two ﬁxed-dose
groups (Figure 3a).
The total number of hospitalisations/ER treatments
was reduced in both budesonide/formoterol groups
compared with the ﬁxed-dose salmeterol/ﬂuticasone
group: there was a 39% rate reduction in the SMART
group (RR 0.61; 95% CI 0.44–0.83; p ¼ 0.0015) and a
32% reduction in the ﬁxed-dose budesonide/formoter-
ol group (RR 0.68; 95% CI 0.51–0.92; p ¼ 0.013; Fig-
ure 3b). The difference between the two budesonide/
formoterol groups was not statistically signiﬁcant.
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Table 2. The total number of days with exacerbations
requiring oral steroid use was reduced by 41–45%
with SMART compared with both ﬁxed-dose regi-
mens. Moreover, compared with ﬁxed-dose treat-
ment, SMART reduced the number of days with
exacerbations requiring hospitalisation/ER treatment
by 38–61% (Table 2).
A post hoc analysis, based on interaction between
age-class and treatment, indicated that the size of the
reduction in the overall exacerbation rate in the
SMART group was consistent for adults (aged
‡ 18 years) and adolescents (aged < 18 years) (p ¼
0.84, interaction test). Adults treated with SMART
had a 39% and 29% reduction in severe exacer-
bations vs. ﬁxed-dose salmeterol/ﬂuticasone (p <
0.001) and ﬁxed-dose budesonide/formoterol (p ¼
0.0043) respectively. Similarly, the small number of
adolescents treated with SMART had non-statistically
signiﬁcant reductions in severe exacerbations of 42%
and 24% respectively.
Mild exacerbations
No signiﬁcant differences were seen between the
SMART group and the two ﬁxed-dose regimens in
the number of mild exacerbation days or the time to
Figure 2 Time to ﬁrst severe exacerbation
(deterioration in asthma resulting in
hospitalisation/emergency room
treatment, or the need for oral steroids
for ‡ 3 days). SMART, Symbicort
 
(budesonide/formoterol) maintenance and
reliever therapy
Table 1 Patients’ baseline characteristics
Characteristic
Salmeterol/
ﬂuticasone
(n ¼ 1123)
Budesonide/
formoterol
(n ¼ 1105)
SMART
(n ¼ 1107)
Male, n (%) 484 (43) 448 (41) 479 (43)
Mean age, years (SD) 38 (17) 38 (17) 38 (17)
Age, n (%)
‡ 18 years 912 (81) 892 (81) 908 (82)
12–17 years 211 (19) 213 (19) 197 (18)
Smoking status
Never, n (%) 904 (80) 865 (78) 873 (79)
Previous, n (%) 165 (15) 169 (15) 178 (16)
Current, n (%) 54 (5) 71 (7) 56 (5)
Mean FEV1, % predicted (SD) 73 (14) 73 (14) 72 (14)
Mean FEV1 reversibility, % (SD) 23 (12) 25 (14) 24 (12)
Mean ICS at study entry, lg/day (SD) 744 (230) 750 (262) 740 (240)
LABA use at study entry, n (%) 525 (47) 518 (47) 509 (46)
SMART, Symbicort
  (budesonide/formoterol) maintenance and reliever therapy; FEV1, forced expiratory volume in 1 s;
ICS, inhaled corticosteroid; LABA, long-acting b2-agonist.
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tion days). There was an average of 27 mild exacer-
bation days/patient/6 months in the salmeterol/
ﬂuticasone group, 29 in the ﬁxed-dose budesonide/
formoterol group and 27 in the SMART group.
Overall, 660 (59%), 689 (63%) and 674 (61%)
salmeterol/ﬂuticasone, budesonide/formoterol and
SMART patients, respectively, experienced a mild
exacerbation.
Asthma symptoms
SMART provided similar improvements to ﬁxed-
dose budesonide/formoterol and salmeterol/ﬂutica-
sone in all symptom-control measures used to assess
daily variability in asthma control (Table 3).
Asthma questionnaires
Patients in all three treatment groups reported sim-
ilar improvements in AQLQ(S) and ACQ-5 scores.
Changes of 0.5 units from run-in indicate clinically
relevant improvements in both scores (21,24). These
improvements were indicated by an increase in
AQLQ(S) score of 0.76–0.78 (Figure 4a) and the
reduction in ACQ-5 score of 0.74–0.79 in the three
treatment groups (Figure 4b).
Lung function
FEV1 and PEF values during the run-in and treat-
ment periods are presented in Table 3. No differ-
ences between the three treatment groups in any of
these measures were detected.
Overall treatment load
As-needed reliever medication use is shown in
Table 3. As-needed use was similar in the SMART
and ﬁxed-dose groups, decreasing by 8–9 inhala-
tions/week compared with baseline in all three
groups. The range of daily mean BDP-equivalent
ICS doses [calculations based on GINA estima-
tions of equipotence of ICS in metered doses:
ﬂuticasone 500 lg ¼ budesonide 800 lg ¼ beclo-
methasone 1000 lg (13)] for the three treatment
groups are summarised in Figure 5. While individ-
ual mean doses varied in SMART patients as a
consequence of the treatment concept, there was
an overall reduction in mean ICS dose in the
SMART group compared with both ﬁxed-dose
groups. The overall number of days per treatment
group when oral corticosteroids were required for
asthma was 619 days in the SMART group, 1044
days with budesonide/formoterol and 1132 days
with salmeterol/ﬂuticasone.
Safety
All three treatments were well tolerated and there
were no notable between-group differences in the
number or severity of adverse events. The most
frequently reported adverse events were upper res-
piratory tract infection, pharyngitis and nasophar-
yngitis. The incidence of pharmacologically
predictable adverse events related to ICS and LABA
use was low and comparable in all treatment
groups.
Table 2 Exacerbation burden
Exacerbation burden
Salmeterol/
ﬂuticasone
Budesonide/
formoterol SMART
Treatment comparison of hazard ratios (95% CI)
SMART vs.
salmeterol/
ﬂuticasone
SMART vs.
budesonide/
formoterol
Budesonide/formoterol
vs. salmeterol/
ﬂuticasone
All event types
No. patients having at least one
severe exacerbation (%)*
138 (12) 126 (11) 94 (9) 0.67 (0.52, 0.87);
p ¼ 0.003
0.74 (0.56, 0.96);
p ¼ 0.026
0.91 (0.72, 1.16);
p ¼ 0.45
Rate/100 patients/6 months 19 16 12 0.61 (0.49, 0.76);
p < 0.001
0.72 (0.57, 0.90);
p ¼ 0.0048
0.85 (0.69, 1.04);
p ¼ 0.1
Total no. severe exacerbations
(total no. days with event)
208 (1327) 173 (1143) 125 (692)
Hospitalisation/ER treatment
No. patients having at least one
hospitalisation/ER treatment (%)*
70 (6) 50 (5) 48 (4) 0.69 (0.48, 0.99);
p ¼ 0.047
0.97 (0.65, 1.44);
p ¼ 0.87
0.71 (0.49, 1.02);
p ¼ 0.066
Rate/100 patients/6 months 8 5 5 0.61 (0.44, 0.83);
p ¼ 0.0015
0.88 (0.63, 1.24);
p ¼ 0.47
0.68 (0.51, 0.92);
p ¼ 0.013
Total no. events (total no.
days with event)
106 (278) 72 (174) 64 (108)
*Cox proportional hazards model of time to ﬁrst severe exacerbation; Comparisons of relative rates from a Poisson regression. SMART, Symbicort
 
(budesonide/formoterol) maintenance and reliever therapy; ER, emergency room.
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incidence was comparable across all three treatment
groups: 32 patients (3%) in the salmeterol/ﬂuticasone
group, 39 patients (4%) in the ﬁxed-dose budesonide/
formoterol group and 31 patients (3%) in the SMART
group experienced such events. Four serious adverse
events were considered by the investigator to be caus-
ally related to the study drug: three in the SMART
group (pneumonia, gastritis and asthma) and one in
the salmeterol/ﬂuticasone group (asthma).
Two deaths occurred during the study, one in the
SMART group (respiratory failure) and one in the
salmeterol/ﬂuticasone group (cardiac failure). Neither
death was considered by the investigator to be caus-
ally related to the study drug.
Discussion
This study validates the concept of SMART. Redu-
cing the maintenance dose of budesonide/formoterol
by 50% and using budesonide/formoterol as reliever
medication instead of terbutaline reduces the risk
and rate of severe exacerbations in adults and adoles-
cents with asthma compared with a higher mainten-
ance dose of ﬁxed-dose budesonide/formoterol or
salmeterol/ﬂuticasone. Other measures of daily
asthma control were similar across the three treat-
ment groups. This improvement in the outcome of
asthma treatment was seen even though the total
dose of ICS administered using the SMART regimen
was 25% lower in BDP equivalents than those
administered in the ﬁxed-dose regimens. Thus, while
conventional ﬁxed-dose combination therapy can
provide well-controlled asthma for many patients,
similar improvements can be achieved with the
SMART approach while further reducing exacerba-
tions and drug load.
The reduction in exacerbations and associated
medical care was substantial. Patients in the
SMART group had 28–39% fewer exacerbations
than those in the ﬁxed-dose groups. Extrapolating
these 6-month data to a 1-year period suggests
Figure 3 Cumulative rate of (A) severe
exacerbations and (B) hospitalisations/
emergency room treatments caused by
asthma; p-values are derived from relative
rate analysis (Poisson regression analysis).
SMART, Symbicort
  (budesonide/
formoterol) maintenance and reliever
therapy
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SMART compared with ﬁxed-dose salmeterol/ﬂuti-
casone and ﬁxed-dose budesonide/formoterol would
prevent 15 and 9 severe exacerbations respectively
(the number needed to treat to prevent one
exacerbation was 7 and 11 respectively). There
were fewer exacerbations requiring hospitalisation
or ER treatment in the SMART group, with such
events occurring on 61% fewer days compared
with salmeterol/ﬂuticasone and on 38% fewer days
compared with ﬁxed double-dose budesonide/for-
moterol. Exacerbations leading to ER treatment or
hospitalisation were approximately 1 day longer on
average (based on the number of days with these
events) in the ﬁxed-dose salmeterol/ﬂuticasone vs.
the SMART group.
It seems unlikely that the reduced number of
SMART patients who still experienced exacerbations
did so as a result of using a maintenance dose that
was too low. All patients using ﬁxed-combination
ICS/LABA in our study received the equivalent of
the maximally effective dose used in the landmark
FACET exacerbation study (25). With SMART, the
average dose used approached 75% of the FACET
dose. Nevertheless, SMART resulted in further reduc-
tions in exacerbations of all types vs. both ﬁxed-dose
groups. This suggests that the SMART approach has
exceeded a previous gold standard for exacerbation
control, while reducing overall steroid and LABA
doses.
The precise reason for the overall reduction in
exacerbations with the SMART approach remains to
Table 3 Clinical outcomes
Efﬁcacy end-point
Salmeterol/
ﬂuticasone
Budesonide/
formoterol SMART
Treatment comparison of clinical outcomes: mean difference (95% CI)
SMART vs. salmeterol/
ﬂuticasone
SMART vs. budesonide/
formoterol
Budesonide/formoterol vs.
salmeterol/ﬂuticasone
Asthma symptoms
Total score (0–6)
Run-in 1.93 1.93 1.91 0.04 ()0.03, 0.10) 0.00 ()0.07, 0.06) 0.04 ()0.02, 0.11)
Treatment 1.03 1.07 1.06
Symptom-free days (%)
Run-in 8.6 8.8 9.3 )2.5 ()5.3, 0.3) )0.8 ()3.6, 2.0) )1.6 ()4.4, 1.2)
Treatment 46.0 44.6 44.2
Asthma-control days* (%)
Run-in 5.7 5.9 5.8 )2.6 ()5.4, 0.2) )0.7 ()3.6, 2.1) )1.9 ()4.7, 1.0)
Treatment 43.7 42.2 41.3
Night-time awakenings (%)
Run-in 31.5 32.8 33.7 )0.8 ()2.4, 0.9) )1.0 ()2.6, 0.7) 0.2 ()1.4, 1.8)
Treatment 14.0 14.6 14.1
Use of as-needed medication
Total no. inhalations/day
Run-in 2.33 2.31 2.29 0.07 ()0.02, 0.16) )0.03 ()0.12, 0.06) 0.10 (0.01, 0.19)
Treatment 0.96 1.05 1.02
As-needed-free days (%)
Run-in 8.8 8.8 8.9 )3.2 ()6.0, )0.5) )1.8 ()4.6, 1.0) )1.4 ()4.2, 1.4)
Treatment 59.1 57.8 56.0
Lung function
FEV1 (l)
Visit 2 2.43 2.42 2.44 0.006 ()0.025, 0.037) 0.005 ()0.026, 0.037) 0.000 ()0.031, 0.031)
Visit 3–5 (mean) 2.67 2.66 2.69
Morning PEF (l/min)
Run-in 338 335 337 )3.2 ()6.9, 0.4) )0.7 ()4.5, 3.0) )2.5 ()6.2, 1.2)
Treatment 367 362 363
Evening PEF (l/min)
Run-in 347 344 346 )1.3 ()4.9, 2.3) )0.6 ()4.3, 3.0) )0.7 ()4.3, 3.0)
Treatment 370 366 368
*Asthma-control days were deﬁned as a day with no symptoms (day or night), no awakenings caused by asthma and no as-needed medication use; Statistically
different at the 5% level of signiﬁcance. SMART, Symbicort
  (budesonide/formoterol) maintenance and reliever therapy; FEV1, forced expiratory volume in 1 s;
PEF, peak expiratory ﬂow; CI, conﬁdence interval.
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from as-needed formoterol and budesonide are likely
to contribute to the overall efﬁcacy of this treatment.
As-needed treatment immediately following exposure
to environmental triggers that lead to a temporary loss
of symptom control is likely to result in an increase in
controller therapy in line with disease activity. During
periods when asthma control is stable, with no need
for symptom relief (56% of study days), patients using
the SMART approach default solely to maintenance
budesonide/formoterol, but at half the daily dose com-
pared with the ﬁxed-dose regimen. Thus, maintenance
plus as-needed budesonide/formoterol responds more
effectively and efﬁciently to the natural variations in
asthma control that are evident even when using an
ICS/LABA regimen at a higher daily dose.
Figure 4 Mean overall (A) Asthma Quality of Life Questionnaire (standardised version) [AQLQ(S)] and (B) Asthma
Control Questionnaire (ACQ) scores over the duration of the study. QoL, quality of life; SMART, Symbicort
 
(budesonide/formoterol) maintenance and reliever therapy
Figure 5 Range of daily mean doses of ICS/LABA reported by individual study patients. *Mean ICS doses converted to
BDP equivalents based on GINA (13) guidelines. Compared with ﬁxed-dose budesonide/formoterol treatment, 9 : 1 (ratio:
63% divided by 7%) SMART-treated patients reduced their mean daily dose by at least 160/4.5 lg than increased their
dose by at least 160/4.5 lg. SMART, Symbicort
  (budesonide/formoterol) maintenance and reliever therapy; BDP,
beclomethasone dipropionate
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ted as the deﬁning feature of SMART (9,26,27).
Thus, budesonide-containing reliever therapy can
ensure that an increase in anti-inﬂammatory therapy
is delivered as required during periods of deterior-
ating symptoms and increased need for reliever
medication (28). In our study, SMART patients used
more budesonide/formoterol than the ﬁxed-dose
budesonide/formoterol group on only 13% of days,
with half the dose used on 56% of days. This sug-
gests that the timing of the dose increase, not the
overall dose, is of greater importance. Whether this
beneﬁt is related to dose clustering of the as-needed
ICS over a spread of days, or to the more efﬁcient
spread of the dose throughout the day during peri-
ods of poor control, is not clear.
Studies have shown that increasing the dose and
frequency of administration of ICS improves asthma
control in patients with acute worsenings (29). As
lung tissue concentrations of ICS decline between
maintenance doses (30,31), as-needed ICS may
restore concentrations when the level of ICS can be
suboptimal. In contrast, approaches that rely on a
signiﬁcant deterioration in asthma symptoms and
action plans that instruct patients to double their
ICS dose without an increase in dose frequency have
been demonstrated to be wholly ineffective at pre-
venting exacerbations (32,33).
Marked improvements in daily symptom control
were seen in all three treatment groups, despite
patients in the SMART group using a lower mainten-
ance dose of ICS/LABA. Compared with run-in,
patients in all groups experienced similar improve-
ments in asthma control and quality of life (assessed
by questionnaires) and more asthma-control days
and fewer asthma-related awakenings (assessed by
daily diaries). The increase in day-to-day asthma
control seen in all three groups can be extrapolated
to at least 130 extra days per year with full symptom
control without the use of reliever medication and at
least 64 extra nights per year without awakenings.
There was no evidence of any clinically relevant
between-group differences in any of these control
measures. Numbers of days with symptom ﬂares
(mild exacerbation days) were equally distributed
among the three treatment groups. Furthermore, no
differences in lung function were detected between
the treatment groups, despite lower use of broncho-
dilator therapy (maintenance and as needed) in the
SMART group. The mean daily ICS dose in BDP
equivalents (13) was approximately 750 lg in the
SMART group vs. 1000 lg in both ﬁxed-dose
groups. In total, only eight SMART patients (< 1%)
used a mean dose of budesonide equivalent to
> 2000 lg/day of BDP. The majority of SMART
patients used less ICS and less LABA than in the
ﬁxed-dose budesonide/formoterol group, i.e. for
every SMART patient who took 160/4.5 lg/day of
budesonide/formoterol more than in the ﬁxed-dose
group, there were nine SMART patients using at least
160/4.5 lg/day less. The fact that day-to-day symp-
tom control was similar in all three groups, even
with the clear difference observed in severe exacerba-
tion rates, serves as a reminder that these measures
reﬂect different aspects of asthma control, both of
which need to be considered when evaluating asthma
management programmes. Our results show the
improved control seen with as-needed budesonide/
formoterol using the SMART concept vs. ﬁxed-dose
ICS/LABA + SABA therapy is greater for exacerba-
tions than for minor symptoms. Minor symptoms
dictate the need for an increase in as-needed therapy
to a similar extent in all treatment groups, but with
the SMART asthma management approach this leads
to an increase in anti-inﬂammatory therapy at the
right time, resulting in fewer exacerbations.
Although there were no clinically important differ-
ences between the two ﬁxed-dose groups in the
majority of outcomes, one clinically relevant and sta-
tistically signiﬁcant advantage of budesonide/formo-
terol was observed. Patients treated with ﬁxed-dose
budesonide/formoterol had 32% fewer exacerbations
requiring hospitalisation/ER treatment vs. those in
the salmeterol/ﬂuticasone group. It is noteworthy
that this is the largest study ever performed with two
ﬁxed-dose ICS/LABA combinations and, as such,
may be the ﬁrst study able to detect such differences.
A similar trend was seen in a smaller study (approxi-
mately 200 patients in each group) in which three vs.
eight events required hospitalisation/ER treatment in
patients treated with the same ﬁxed dose of budeso-
nide/formoterol or salmeterol/ﬂuticasone respect-
ively (1). The reasons for this difference remain
unclear and may require further exploratory analysis.
One possible reason may be that formoterol, a full
b2-agonist, is more efﬁcacious than salmeterol, a par-
tial b2-agonist, during periods of increased inﬂam-
mation or challenge (34,35). Another factor may be
the beneﬁcial effects on neutrophilic inﬂammation
that have been described for formoterol but to a
lesser extent for salmeterol (36).
In a controlled clinical setting, SMART has previ-
ously been shown to improve asthma control com-
pared with the same maintenance dose of
budesonide/formoterol plus terbutaline for relief (9).
In a study allowing titration of the maintenance dose
as judged appropriate by the treating physician,
SMART patients had fewer exacerbations and better
asthma control than those receiving salmeterol/ﬂuti-
casone up to a dose of 50/500 lg bid (40% of
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SMART is uniquely effective at reducing exacerba-
tions and their associated morbidity compared with
ﬁxed-dose ICS/LABA, even at a higher daily dose.
The study by Vogelmeier et al. was performed open
label to allow easier maintenance-dose titration; we
have now demonstrated in a very large double-blind
study that SMART leads to fewer exacerbations with
no increase in ﬂuctuations of daily asthma control
compared with a twofold higher maintenance dose
of budesonide/formoterol or a corresponding dose of
salmeterol/ﬂuticasone. The SMART approach has
also been demonstrated to deliver signiﬁcant cost
savings compared with the higher maintenance dose
of budesonide/formoterol or salmeterol/ﬂuticasone
plus terbutaline as needed, when applying 2004 UK
unit costs to the present dataset (37).
In the present study, patients who were infrequent
users of reliever medication were excluded after the
run-in period. This may have excluded a small
minority of patients for whom the beneﬁt of SMART
is unknown. Nonetheless, a recent survey of 1921
patients using regular ICS or ICS/LABA medication
has highlighted that 71% of these patients used their
reliever medication every day and 47% had experi-
enced one or more exacerbations in the previous
year (7), suggesting that the results of the present
study have wide-reaching applicability to real-life
asthma. Finally, this study, in addition to previous
research (9–11), has conﬁrmed that the SMART
treatment approach is well tolerated with no increase
in asthma-related events of any type compared with
higher doses of ICS alone or an alternative combina-
tion ICS/LABA regimen.
In conclusion, compared with a twofold higher
ﬁxed maintenance dose of budesonide/formoterol or
a corresponding dose of salmeterol/ﬂuticasone plus
SABA for relief, SMART reduces the incidence of
severe asthma exacerbations and maintains similar
daily asthma control at a lower overall drug load.
With this combination of increased efﬁcacy and sim-
plicity, the SMART approach represents a signiﬁcant
improvement over ﬁxed, twice-daily combinations of
higher-dose ICS/LABA, which have until now been
regarded as the most effective way to manage moder-
ate and severe persistent asthma.
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